Lumos Diagnostics Holdings Share Price and Company Fundamentals



Price
$1.195
Change
-0.055 (-4.400%)
52 week
1.19 - 1.5

Last traded: Today at 5:55 AM

Lumos Diagnostics Holdings Limited operates as an integrated developer and manufacturer of point-of-care (POC) diagnostic tests. The company develops and manufactures proprietary and in-licensed POC diagnostic tests. Its products include FebriDx, a test that differentiates between bacterial and viral respiratory infections; and CoviDx, an antigen test for COVID-19. The company also develops and manufactures POC diagnostic tests on commercial contract basis, which include POC diagnostic tests, digital reader formats, and digital applications. It offers its products through distributors primarily in the North American and European markets. The company was founded in 2004 and is headquartered in Melbourne, Australia.

Key Metrics

PE ratio

-

PB ratio

-

Dividend yield

Beta

-

Market cap

$179.43M

Enterprise value

$108.03M

Company profile

Primary activitiesDevelopment, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests.
Industry / SectorDiagnostics & Research / Healthcare
Websitehttp://lumosdiagnostics.com
Mailing addressLevel 4 100 Albert Road South Melbourne Melbourne VIC 3205 Australia
Phone / Fax760-683-5374 /
Share registryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED

Dividends

Lumos Diagnostics Holdings does not pay dividends.

Company Executives

As of Jul 2021, following are the company executives and directors listed on Lumos Diagnostics Holdings.

NameTitleAgeTotal Pay
Mr. Samuel LanyonExec. Chairman
Dr. Robert P. Sambursky M.D.CEO & Exec. Director
Ms. Melanie Jaye Leydin C.A., B.Bus, CACFO & Company Sec.47
Mr. Kurt PhinneyVP of Operations
Dr. Sacha Dopheide Ph.D.Chief Technology Officer
Ms. Jill ThompsonSr. VP of Corp. Strategy & Devel.
Ms. Sarah GlubkaSr. Director of HR
Dr. Jeffrey BishopSr. VP R&D
Mr. Aaron ErlandsonSr. VP of Fin.
Ms. Annie BellSr. Director of Medical Affairs

Profitability and management effectiveness

Profit margin

-71.64%

Operating margin

-64.85%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Lumos Diagnostics Holdings is 179.43M and its enterprise value is 108.03M. The enterprise value to revenue ratio of LDX is 6.53.

Companies similar to Lumos Diagnostics Holdings (LDX)

Lumos Diagnostics Holdings (ASX:LDX) Frequently Asked Questions

1. What is Lumos Diagnostics Holdings's Stock Symbol?

Lumos Diagnostics Holdings trades on ASX under the ticker symbol "LDX".

2. What is Lumos Diagnostics Holdings's stock price today?

One share of LDX stock can currently be purchased for approximately $1.195.

3. How can I contact Lumos Diagnostics Holdings?

Lumos Diagnostics Holdings's mailing address is Level 4 100 Albert Road South Melbourne Melbourne VIC 3205 Australia. The company can be reached via phone at 760-683-5374.

4. What is Lumos Diagnostics Holdings's official website?

The official website of Lumos Diagnostics Holdings is http://lumosdiagnostics.com.

5. Which share registry manages Lumos Diagnostics Holdings's stock?

Lumos Diagnostics Holdings's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.